Yao et al. engineered a peptide derived from the amino acid sequence surrounding the C272 site of PD-L1, which competitively inhibited the palmitoylation of endogenous PD-L1 by ZDHHC3, thereby diminishing PD-L1 expression in tumour cells and enhancing T-cell-mediated antitumour immunity 55. Here, ZDHHC3 is linked to neoplasm.